Pfizer's Innovative Drug Pipeline Provides Ample Reason To Buy It Here
Pfizer has faced numerous challenges, including a decline in COVID-19 vaccine demand and high costs, but the worst is likely priced into the stock. The company is focusing on innovation and has amb...
Is Pfizer Stock the Biggest Bargain in the S&P 500?
Pfizer's PEG ratio according to one widely used financial website is shockingly low. This low valuation metric raises questions.
Pfizer: The Market Is Wrong
Over the last twelve months, Pfizer's stock experienced a massive sell-off due to a massive revenue and EPS drop after the COVID-related spikes of 2021 and 2022. However, the company's financial pe...
Will Pfizer's (PFE) New Drugs Provide a Boost to 2024 Sales?
Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.
Pfizer's (PFE) RSV Vaccine Study in Adults Under 60 Meets Goal
Pfizer's (PFE) RSV vaccine, Abrysvo, generates an immune response in a phase III study evaluating it in higher-risk adults aged 18 to 59, non-inferior to that in older adults.
Where Will Pfizer Stock Be in 10 Years?
Drug giant Pfizer has been investing big money into oncology in recent years. In a decade, the company's product mix may look significantly different than today.
RSV Vaccine Could Protect High-Risk Adults Under 60, Pfizer Says
A late-stage trial of Pfizer's RSV vaccine showed promising results in adults under 60 years old, suggesting the shot could help people as young as 18, the company announced Tuesday, amid an effort...
Pfizer Stock Rises on Upbeat RSV Vaccine Trial Data
Pfizer Inc (NYSE PFE) stock is up 1.7% at $27.04 at last check, following news a late-stage trial of its respiratory syncytial virus (RSV) vaccine Abrysvo generated an immune response in higher r...
Pfizer's RSV vaccine shows potential to protect high-risk adults ages 18-59, widening possible use
Pfizer plans to file for an expanded approval of Abrysvo, which is currently approved for adults ages 60 and above and expectant mothers.
Billionaire Ken Griffin Loaded Up on This High-Yield Dividend Stock. Should You?
Ken Griffin's Citadel hedge fund more than quadrupled its stake in this stock in 2023 Q4. Griffin probably likes the stock because of its valuation, dividend, and surprisingly robust growth prospects.
This S&P 500 Dividend Stock Could Be the Best Bad-News Buy on the Market
Pfizer has had plenty of bad news, with more on the way. New products and acquisitions should help the drugmaker return to growth.
4 Dividend Aristocrats Trading at a Discount
The first quarter of the year was a success for investors. The overall market NYSE: SPY surged nearly 10%, fueled by robust economic indicators, optimism, and hype surrounding AI.
Prediction: Pfizer Won't Acquire Viking Therapeutics. Here's Why.
Viking Therapeutics may be on the verge of a breakthrough obesity care treatment. Right now, obesity care and diabetes are dominated by Novo Nordisk and Eli Lilly.
Will Pfizer Be a Trillion-Dollar Stock by 2035?
Pfizer would need to generate exceptional growth to reach a market cap of $1 trillion by 2035. Several obstacles could make achieving this goal difficult.
Related Companies